Pneumonia

The novel 21-valent pneumococcal vaccine remains on track for the FDA PDUFA date of June 17, 2024; Merck adds this new data to the body of positive evidence.

If approved the 21-valent shot would be the first pneumococcal conjugate vaccine indicated specifically for adults.

Data presented at CHEST 2023 shows treatment with hydrocortisone is associated with a decrease in morality among patients with community-acquired pneumonia.

Statistically significant positive immune responses were observed in both vaccine-naive adults and those previously vaccinated, including for the vaccine's 8 unique serotypes.

New CDC recommendations for pneumococcal vaccination for persons aged 19 to 64 years could require some extra thought. This 4-question quiz tests your knowledge.

Get a quick topline look at specific revisions and additions included in the ACIP's recommendations for routine immunization of those aged ≥19 years in the US.

Respiratory syncytial virus is an age-old winter foe that could affect many of your patients this year. Take a minute and scan these facts for a refresher.

In persons with COPD, seasonal influenza and PPSV23 vaccines, separately or together, reduced the risk for COPD- and pneumonia-related hospitalizations.

The 21-valent pneumococcal conjugate vaccine targets 85% of invasive pneumococcal disease in adults aged ≥65 years; 8 serotypes are exclusive to this vaccine, says Merck.

How much do you know about diphtheria and the vaccine? Answer these 2 questions to find out.